Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Fiche publication
Date publication
décembre 2014
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CADIOT Guillaume, Pr KURTZ Jean-Emmanuel, Dr BENGRINE-LEFEVRE Leila
Tous les auteurs :
Mitry E, Walter T, Baudin E, Kurtz JE, Ruszniewski P, Dominguez-Tinajero S, Bengrine-Lefevre L, Cadiot G, Dromain C, Farace F, Rougier P, Ducreux M
Lien Pubmed
Résumé
Gastro-intestinal neuroendocrine tumours (GI-NETs) are chemotherapy-resistant tumours. Bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF), has shown promising results in several phase II trials of gastro-entero-pancreatic-NETs. We assessed bevacizumab combined with capecitabine, specifically in GI-NET patients.
Mots clés
Administration, Oral, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Bevacizumab, Capecitabine, Deoxycytidine, administration & dosage, Disease-Free Survival, Female, Fluorouracil, administration & dosage, Gastrointestinal Neoplasms, drug therapy, Humans, Infusions, Intravenous, Male, Middle Aged, Neuroendocrine Tumors, drug therapy, Treatment Outcome
Référence
Eur. J. Cancer. 2014 Dec;50(18):3107-15